USP is launching a new program, Impurities for Development (IfD), to assist manufacturers in their drug development efforts and help them meet quality standards and regulatory requirements to control impurities that may be harmful to patients. Characterizing and controlling impurities in drugs under development can present significant challenges to manufacturers because they can occur for several reasons:  arising naturally within the source materials, being added as part of a product’s synth...